Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2014

01-09-2014 | Letter

Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs

Authors: Sarah E. Holden, Christian A. Bannister, Craig J. Currie

Published in: Diabetologia | Issue 9/2014

Login to get access

Excerpt

To the Editor: We read the article by Ranc and colleagues with interest [1]; however, we have concerns about its value. This large-scale study investigated the differences in survival following incident cancer in people with and without diabetes, accounting for diabetes treatment and diabetes duration. …
Literature
1.
Ranc K, Jørgensen ME, Friis S, Carstensen B (2014) Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia 57:927–934PubMedCrossRef
2.
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273PubMedCrossRef
3.
Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777PubMedCrossRef
Metadata
Title
Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs
Authors
Sarah E. Holden
Christian A. Bannister
Craig J. Currie
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 9/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3281-1

Other articles of this Issue 9/2014

Diabetologia 9/2014 Go to the issue

Article

Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study

Article

Fine-tuned iron availability is essential to achieve optimal adipocyte differentiation and mitochondrial biogenesis

Article

Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)

Article

GAD autoantibody affinity in schoolchildren from the general population

Research Letter

Fate of abstracts submitted to the 2004 EASD Annual Meeting in Munich

Article

Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits